Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04131595 · ClinicalTrials.gov registry record · Phase 1
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
A Phase 1 study of Equine Encephalitis, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04131595: Completed Phase 1 study of Equine Encephalitis, sponsored by Bavarian Nordic.
NCT04131595 is a Phase 1 study of Equine Encephalitis that has completed, run by Bavarian Nordic. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04131595, a Phase 1 study of Equine Encephalitis, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
Primary Outcome
Number of subjects reporting any serious adverse events (SAE)
Conditions Studied
Interventions
- BIOLOGICAL MVA-BN-WEV Dose 1
- BIOLOGICAL MVA-BN-WEV Dose 2
- BIOLOGICAL MVA-BN-WEV Dose 3
Study Locations (1)
Kansas
- Johnson County Clin-Trials - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2020-07-22 |
| Phase | Phase 1 |
What the finished NCT04131595 record still lists
NCT04131595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Equine Encephalitis appearing as the primary indexed condition, and to 3 interventions - of which MVA-BN-WEV Dose 1 is the first listed.
NCT04131595 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT04131595 about?
NCT04131595 is a clinical study titled "Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects". To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
What is the current status of trial NCT04131595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2019-10-07. Estimated completion is 2020-07-22.
What conditions does trial NCT04131595 study?
This clinical trial studies the following conditions: Equine Encephalitis.
What interventions are being tested in trial NCT04131595?
The interventions under investigation include: MVA-BN-WEV Dose 1 (BIOLOGICAL), MVA-BN-WEV Dose 2 (BIOLOGICAL), MVA-BN-WEV Dose 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04131595?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04131595 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04131595's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI